Brevan Howard Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Brevan Howard Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.46M	Buy	+6,447	New	+$3.3M	0.03%	492
2026 Q1	–	Sell	-3,632	Closed	-$2.12M	–	2341
2025 Q4	$2.12M	Buy	3,632 +2,257	+164%	+$1.15M	0.02%	472
2025 Q3	$631K	Buy	1,375 +209	+18%	+$78K	﹤0.01%	1164
2025 Q2	$353K	Buy	+1,166	New	+$347K	﹤0.01%	1492
2025 Q1	–	Sell	-1,001	Closed	-$309K	–	1336
2024 Q4	$309K	Buy	+1,001	New	+$282K	﹤0.01%	763
2024 Q1	–	Sell	-2,293	Closed	-$531K	–	1213
2023 Q4	$531K	Buy	+2,293	New	+$401K	0.01%	452

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Brevan Howard Capital Management's MDGL Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 6,447 shares worth $3.46M. The stake represents 0.03% of the portfolio and ranks #492 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in MDGL as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in MDGL in Q4 2023 and has held it in 6 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Brevan Howard Capital Management held 6,447 shares of Madrigal Pharmaceuticals worth $3.46M as of Q2 2026.
Madrigal Pharmaceuticals was a new Brevan Howard Capital Management position in Q2 2026.
Madrigal Pharmaceuticals made up 0.03% of Brevan Howard Capital Management's portfolio in Q2 2026, its #492 holding.
Brevan Howard Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.